Compare UPBD & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | SPTX |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1996 | 2026 |
| Metric | UPBD | SPTX |
|---|---|---|
| Price | $21.91 | $21.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $32.25 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 179.3K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $4,695,061,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.47 | N/A |
| P/E Ratio | $35.56 | ★ N/A |
| Revenue Growth | ★ 8.67 | N/A |
| 52 Week Low | $15.82 | $17.59 |
| 52 Week High | $28.03 | $22.98 |
| Indicator | UPBD | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.53 | 58.39 |
| Support Level | $16.88 | $18.47 |
| Resistance Level | $23.93 | $22.15 |
| Average True Range (ATR) | 0.91 | 1.94 |
| MACD | 0.09 | -0.04 |
| Stochastic Oscillator | 66.19 | 74.34 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions, Mexico segment offers lease-to-own stores in Mexico. The The Brigit segment offers various financial health products and tools to help users improve their financial health. The company derives a majority of its revenue from the Acima segment.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.